<h3>關鍵洞察</h3>
<ul>
<li>個人投資者在 Corvus Pharmaceuticals 的大量持股表明，他們在管理和商業戰略上有更大的發言權</li>
<li>前 12 大股東持有公司 51% 的股份</li>
<li>Corvus Pharmaceuticals 的機構持股比例為 37%</li>
</ul>
<p>特朗普承諾要 &#34;釋放&#34; 美國的石油和天然氣，這 15 只美國股票的發展有望受益。</p>
<p>要了解誰真正控制着 Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)，瞭解公司的所有權結構至關重要。而持有最大份額的羣體是個人投資者，擁有 40% 的股份。換句話説，這個羣體在對公司的投資中將獲得最多的收益（或承受最多的損失）。</p>
<p>在上週股價上漲 12% 後，個人投資者獲利最多，但持有 37% 股票的機構投資者也從中受益。</p>
<p>讓我們深入探討 Corvus Pharmaceuticals 各類股東的情況，從下面的圖表開始。</p>
<p>查看我們對 Corvus Pharmaceuticals 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/279359732-ownership-breakdown-1-dark-2/1758795234183?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/279359732-ownership-breakdown-1-dark-2/1758795234183"/></p>
<p>NasdaqGM:CRVS 所有權結構 2025 年 9 月 25 日</p>
<h2>機構持股對 Corvus Pharmaceuticals 的啓示是什麼？</h2>
<p>機構投資者通常將自己的回報與一個常見的基準指數的回報進行比較。因此，他們通常會考慮購買包含在相關基準指數中的大型公司。</p>
<p>我們可以看到 Corvus Pharmaceuticals 確實有機構投資者，他們持有公司相當一部分的股票。這意味着為這些機構工作的分析師已經關注了這隻股票，並且他們對其表示認可。但和其他人一樣，他們也可能會出錯。如果兩家大型機構投資者同時試圖拋售一隻股票，股價大幅下跌並不罕見。因此，查看 Corvus Pharmaceuticals 過去的盈利軌跡是值得的（見下文）。當然，還要記住還有其他因素需要考慮。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/279359732-earnings-and-revenue-growth-1-dark-2/1758795236591?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/279359732-earnings-and-revenue-growth-1-dark-2/1758795236591"/></p>
<p>NasdaqGM:CRVS 盈利和收入增長 2025 年 9 月 25 日</p>
<p>我們的數據顯示對沖基金持有 Corvus Pharmaceuticals 9.5% 的股份。這一點值得注意，因為對沖基金通常是相當活躍的投資者，可能會試圖影響管理層。許多人希望在短期或中期內看到價值創造（和更高的股價）。根據我們的數據，我們可以看到最大股東是 OrbiMed Advisors LLC，持有 9.6% 的流通股。作為對比，第二大股東持有約 9.5% 的流通股，第三大股東持有 5.7%。此外，首席執行官 Richard Miller 擁有公司 3.1% 的股份。</p>
<p>更仔細地查看我們的所有權數據表明，前 12 大股東的合計持股比例為 51%，這意味着沒有單一股東擁有多數股份。</p>
<p>雖然研究一家公司的機構持股可以為您的研究增值，但研究分析師的推薦也是一個好習慣，以更深入地瞭解股票的預期表現。有相當數量的分析師覆蓋這隻股票，因此瞭解他們對未來的整體看法可能會很有用。</p>
<h2>Corvus Pharmaceuticals 的內部持股</h2>
<p>雖然內部人的確切定義可能是主觀的，但幾乎所有人都認為董事會成員是內部人。公司管理層向董事會負責，而董事會應代表股東的利益。值得注意的是，有時高層管理人員本身也在董事會中。</p>
<p>大多數人認為內部持股是積極的，因為它可以表明董事會與其他股東的利益一致。然而，有時過多的權力集中在這個羣體中。</p>
<p>我們可以報告，內部人確實持有 Corvus Pharmaceuticals, Inc. 的股份。作為個人，內部人共同持有價值 1800 萬美元的公司股份，總市值為 4.56 億美元。看到內部人進行一些投資是件好事，但可能值得檢查這些內部人是否在增持。</p>
<h2>公眾持股</h2>
<p>公眾持有 40% 的股份，主要由個人投資者組成，對 Corvus Pharmaceuticals 有一定的影響力。雖然這種持股規模可能不足以在政策決策中影響他們的利益，但他們仍然可以對公司政策產生集體影響。</p>
<h2>私募股權持股</h2>
<p>私募股權公司持有 Corvus Pharmaceuticals 9.6% 的股份。這表明他們在關鍵政策決策中可能具有影響力。有時我們看到私募股權公司會長期持有，但一般來説，他們的投資週期較短，正如其名所示，他們不太會投資於上市公司。經過一段時間，他們可能會考慮出售並將資本重新部署到其他地方。</p>
<h2>下一步：</h2>
<p>考慮擁有公司股份的不同羣體總是值得的。但要更好地理解 Corvus Pharmaceuticals，我們需要考慮許多其他因素。例如，風險 - Corvus Pharmaceuticals 有 <strong>3 個警告信號</strong>（其中 1 個是顯著的），我們認為您應該瞭解。</p>
<p>但最終 <strong>未來</strong> 而不是過去，將決定這家公司的所有者將如何表現。因此，我們認為查看這份免費的報告是明智的，該報告顯示分析師是否預測更光明的未來。</p>
<p>注意：本文中的數據是根據過去 12 個月的數據計算得出的，指的是財務報表日期所在月份的最後一天結束的 12 個月期間。這可能與全年年報數據不一致。</p>

Corvus制藥

<p>Corvus Pharmaceuticals, Inc.（納斯達克代碼：CRVS）上週股價上漲了 12%，使個人和機構投資者均受益。個人投資者持有公司 40% 的股份，給予他們對管理和戰略的顯著影響力，而機構投資者則擁有 37% 的股份。前 12 大股東合計持有 51% 的股份，表明沒有單一的多數股東。對沖基金持有 9.5% 的股份，內部人士持有價值 1800 萬美元的股份。公眾持有 40% 的股份，使其在公司政策上具有一定的影響力，而私募股權公司持有 9.6% 的股份，暗示在關鍵決策中可能具有影響力</p>

<h3>Key Insights</h3>
<div class="lb-trans"><h3>關鍵洞察</h3>
</div><ul>
<li>The considerable ownership by individual investors in Corvus Pharmaceuticals indicates that they collectively have a greater say in management and business strategy</li>
<li>51% of the business is held by the top 12 shareholders</li>
<li>Institutional ownership in Corvus Pharmaceuticals is 37%</li>
</ul>
<div class="lb-trans"><ul>
<li>個人投資者在 Corvus Pharmaceuticals 的大量持股表明，他們在管理和商業戰略上有更大的發言權</li>
<li>前 12 大股東持有公司 51% 的股份</li>
<li>Corvus Pharmaceuticals 的機構持股比例為 37%</li>
</ul>
</div><p>Trump has pledged to &#34;unleash&#34; American oil and gas and these 15 US stocks have developments that are poised to benefit.</p>
<div class="lb-trans"><p>特朗普承諾要 &#34;釋放&#34; 美國的石油和天然氣，這 15 只美國股票的發展有望受益。</p>
</div><p>To get a sense of who is truly in control of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), it is important to understand the ownership structure of the business. And the group that holds the biggest piece of the pie are individual investors with 40% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.</p>
<div class="lb-trans"><p>要了解誰真正控制着 Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)，瞭解公司的所有權結構至關重要。而持有最大份額的羣體是個人投資者，擁有 40% 的股份。換句話説，這個羣體在對公司的投資中將獲得最多的收益（或承受最多的損失）。</p>
</div><p>Following a 12% increase in the stock price last week, individual investors profited the most, but institutions who own 37% stock also stood to gain from the increase.</p>
<div class="lb-trans"><p>在上週股價上漲 12% 後，個人投資者獲利最多，但持有 37% 股票的機構投資者也從中受益。</p>
</div><p>Let's delve deeper into each type of owner of Corvus Pharmaceuticals, beginning with the chart below.</p>
<div class="lb-trans"><p>讓我們深入探討 Corvus Pharmaceuticals 各類股東的情況，從下面的圖表開始。</p>
</div><p>View our latest analysis for Corvus Pharmaceuticals</p>
<div class="lb-trans"><p>查看我們對 Corvus Pharmaceuticals 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/279359732-ownership-breakdown-1-dark-2/1758795234183" alt="" original-src="https://images.simplywall.st/asset/chart/279359732-ownership-breakdown-1-dark-2/1758795234183"/></p>
<p>NasdaqGM:CRVS Ownership Breakdown September 25th 2025</p>
<div class="lb-trans"><p>NasdaqGM:CRVS 所有權結構 2025 年 9 月 25 日</p>
</div><h2>What Does The Institutional Ownership Tell Us About Corvus Pharmaceuticals?</h2>
<div class="lb-trans"><h2>機構持股對 Corvus Pharmaceuticals 的啓示是什麼？</h2>
</div><p>Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.</p>
<div class="lb-trans"><p>機構投資者通常將自己的回報與一個常見的基準指數的回報進行比較。因此，他們通常會考慮購買包含在相關基準指數中的大型公司。</p>
</div><p>We can see that Corvus Pharmaceuticals does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Corvus Pharmaceuticals, (below). Of course, keep in mind that there are other factors to consider, too.</p>
<div class="lb-trans"><p>我們可以看到 Corvus Pharmaceuticals 確實有機構投資者，他們持有公司相當一部分的股票。這意味着為這些機構工作的分析師已經關注了這隻股票，並且他們對其表示認可。但和其他人一樣，他們也可能會出錯。如果兩家大型機構投資者同時試圖拋售一隻股票，股價大幅下跌並不罕見。因此，查看 Corvus Pharmaceuticals 過去的盈利軌跡是值得的（見下文）。當然，還要記住還有其他因素需要考慮。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/279359732-earnings-and-revenue-growth-1-dark-2/1758795236591" alt="" original-src="https://images.simplywall.st/asset/chart/279359732-earnings-and-revenue-growth-1-dark-2/1758795236591"/></p>
<p>NasdaqGM:CRVS Earnings and Revenue Growth September 25th 2025</p>
<div class="lb-trans"><p>NasdaqGM:CRVS 盈利和收入增長 2025 年 9 月 25 日</p>
</div><p>Our data indicates that hedge funds own 9.5% of Corvus Pharmaceuticals. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation (and a higher share price) in the short term or medium term. Looking at our data, we can see that the largest shareholder is OrbiMed Advisors LLC with 9.6% of shares outstanding. For context, the second largest shareholder holds about 9.5% of the shares outstanding, followed by an ownership of 5.7% by the third-largest shareholder. Furthermore, CEO Richard Miller is the owner of 3.1% of the company's shares.</p>
<div class="lb-trans"><p>我們的數據顯示對沖基金持有 Corvus Pharmaceuticals 9.5% 的股份。這一點值得注意，因為對沖基金通常是相當活躍的投資者，可能會試圖影響管理層。許多人希望在短期或中期內看到價值創造（和更高的股價）。根據我們的數據，我們可以看到最大股東是 OrbiMed Advisors LLC，持有 9.6% 的流通股。作為對比，第二大股東持有約 9.5% 的流通股，第三大股東持有 5.7%。此外，首席執行官 Richard Miller 擁有公司 3.1% 的股份。</p>
</div><p>A closer look at our ownership figures suggests that the top 12 shareholders have a combined ownership of 51% implying that no single shareholder has a majority.</p>
<div class="lb-trans"><p>更仔細地查看我們的所有權數據表明，前 12 大股東的合計持股比例為 51%，這意味着沒有單一股東擁有多數股份。</p>
</div><p>While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.</p>
<div class="lb-trans"><p>雖然研究一家公司的機構持股可以為您的研究增值，但研究分析師的推薦也是一個好習慣，以更深入地瞭解股票的預期表現。有相當數量的分析師覆蓋這隻股票，因此瞭解他們對未來的整體看法可能會很有用。</p>
</div><h2>Insider Ownership Of Corvus Pharmaceuticals</h2>
<div class="lb-trans"><h2>Corvus Pharmaceuticals 的內部持股</h2>
</div><p>While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.</p>
<div class="lb-trans"><p>雖然內部人的確切定義可能是主觀的，但幾乎所有人都認為董事會成員是內部人。公司管理層向董事會負責，而董事會應代表股東的利益。值得注意的是，有時高層管理人員本身也在董事會中。</p>
</div><p>Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.</p>
<div class="lb-trans"><p>大多數人認為內部持股是積極的，因為它可以表明董事會與其他股東的利益一致。然而，有時過多的權力集中在這個羣體中。</p>
</div><p>We can report that insiders do own shares in Corvus Pharmaceuticals, Inc.. As individuals, the insiders collectively own US$18m worth of the US$456m company. It is good to see some investment by insiders, but it might be worth checking if those insiders have been buying.</p>
<div class="lb-trans"><p>我們可以報告，內部人確實持有 Corvus Pharmaceuticals, Inc. 的股份。作為個人，內部人共同持有價值 1800 萬美元的公司股份，總市值為 4.56 億美元。看到內部人進行一些投資是件好事，但可能值得檢查這些內部人是否在增持。</p>
</div><h2>General Public Ownership</h2>
<div class="lb-trans"><h2>公眾持股</h2>
</div><p>With a 40% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Corvus Pharmaceuticals. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.</p>
<div class="lb-trans"><p>公眾持有 40% 的股份，主要由個人投資者組成，對 Corvus Pharmaceuticals 有一定的影響力。雖然這種持股規模可能不足以在政策決策中影響他們的利益，但他們仍然可以對公司政策產生集體影響。</p>
</div><h2>Private Equity Ownership</h2>
<div class="lb-trans"><h2>私募股權持股</h2>
</div><p>Private equity firms hold a 9.6% stake in Corvus Pharmaceuticals. This suggests they can be influential in key policy decisions. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere.</p>
<div class="lb-trans"><p>私募股權公司持有 Corvus Pharmaceuticals 9.6% 的股份。這表明他們在關鍵政策決策中可能具有影響力。有時我們看到私募股權公司會長期持有，但一般來説，他們的投資週期較短，正如其名所示，他們不太會投資於上市公司。經過一段時間，他們可能會考慮出售並將資本重新部署到其他地方。</p>
</div><h2>Next Steps:</h2>
<div class="lb-trans"><h2>下一步：</h2>
</div><p>It's always worth thinking about the different groups who own shares in a company. But to understand Corvus Pharmaceuticals better, we need to consider many other factors. Take risks for example - Corvus Pharmaceuticals has <strong>3 warning signs</strong> (and 1 which is significant) we think you should know about.</p>
<div class="lb-trans"><p>考慮擁有公司股份的不同羣體總是值得的。但要更好地理解 Corvus Pharmaceuticals，我們需要考慮許多其他因素。例如，風險 - Corvus Pharmaceuticals 有 <strong>3 個警告信號</strong>（其中 1 個是顯著的），我們認為您應該瞭解。</p>
</div><p>But ultimately <strong>it is the future</strong>, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.</p>
<div class="lb-trans"><p>但最終 <strong>未來</strong> 而不是過去，將決定這家公司的所有者將如何表現。因此，我們認為查看這份免費的報告是明智的，該報告顯示分析師是否預測更光明的未來。</p>
</div><p>NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.</p>
<div class="lb-trans"><p>注意：本文中的數據是根據過去 12 個月的數據計算得出的，指的是財務報表日期所在月份的最後一天結束的 12 個月期間。這可能與全年年報數據不一致。</p>
</div>

While institutions invested in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) benefited from last week's 12% gain, individual investors stood to gain the most

儘管機構投資者從上週 Corvus 製藥公司（NASDAQ:CRVS）12% 的漲幅中受益，但個人投資者的收益最大